Table 1 Patient characteristics at metastatic diagnosis, treatment lines received during follow up, and median survival by metastatic subtype
Patient characteristics at metastatic diagnosis (M1) | |||||||
|---|---|---|---|---|---|---|---|
All | Luminal A | Luminal B | HER2+/ER- | HER2+/Luminal | Triple negative | Unclassified | |
(n = 370) | (n = 118) | (n = 119) | (n = 31) | (n = 38) | (n = 46) | (n = 18) | |
Age at M1 dx, years | |||||||
mean (SD) | 67.2 (13.6) | 69.7 (12.2) | 67.0 (12.9) | 61.8 (15.4) | 63.0 (15.4) | 64.8 (13.2) | 75.6 (13.6) |
median (IQR) | 67.6 (59.2–77.2) | 69.1 (61.7–79.2) | 69.0 (59.2–75.4) | 62.0 (52.8–72.2) | 65.3 (47.6–72.7) | 64.5 (56.1–76.0) | 80.7 (66.5–85.5) |
< 50 | 50 (13.5%) | 9 (7.6%) | 18 (15.1%) | 5 (16.1%) | 12 (31.6%) | 6 (13.0%) | 0 (0.0%) |
50–60 | 49 (13.2%) | 13 (11.0%) | 13 (10.9%) | 8 (25.8%) | 4 (10.5%) | 8 (17.4%) | 3 (16.7%) |
60–70 | 105 (28.4%) | 40 (33.9%) | 31 (26.1%) | 8 (25.8%) | 7 (18.4%) | 17 (37.0%) | 2 (11.1%) |
70–80 | 94 (25.4%) | 31 (26.3%) | 39 (32.8%) | 7 (22.6%) | 7 (18.4%) | 7 (15.2%) | 3 (16.7%) |
80+ | 72 (19.5%) | 25 (21.2%) | 18 (15.1%) | 3 (9.7%) | 8 (21.1%) | 8 (17.4%) | 10 (55.6%) |
Time since primary dx, months | |||||||
mean (SD) | 72.0 (80.7) | 87.2 (84.7) | 66.2 (73.0) | 28.7 (42.1) | 46.5 (52.4) | 52.3 (71.9) | 189.6 (100.0) |
median (IQR) | 39.3 (7.0–109.4) | 68.1 (6.3–128.5) | 37.3 (11.5–94.9) | 4.1 (0.7–39.2) | 30.1 (3.2–63.2) | 28.4 (13.1–42.0) | 184.5 (145.0–232.3) |
0–3 | 81 (21.9%) | 29 (24.6%) | 22 (18.5%) | 15 (48.4%) | 9 (23.7%) | 5 (10.9%) | 1 (5.6%) |
3–12 | 21 (5.7%) | 2 (1.7%) | 8 (6.7%) | 2 (6.5%) | 4 (10.5%) | 5 (10.9%) | 0 (0.0%) |
12–36 | 68 (18.4%) | 9 (7.6%) | 28 (23.5%) | 3 (9.7%) | 7 (18.4%) | 21 (45.7%) | 0 (0.0%) |
36–60 | 40 (10.8%) | 11 (9.3%) | 12 (10.1%) | 5 (16.1%) | 7 (18.4%) | 5 (10.9%) | 0 (0.0%) |
60+ | 160 (43.2%) | 67 (56.8%) | 49 (41.2%) | 6 (19.4%) | 11 (28.9%) | 10 (21.7%) | 17 (94.4%) |
Year at M1 dx, n (%) | |||||||
2009–2011 | 157 (42.4%) | 56 (47.5%) | 51 (42.9%) | 12 (38.7%) | 9 (23.7%) | 22 (47.8%) | 7 (38.9%) |
2012–2014 | 142 (38.4%) | 38 (32.2%) | 45 (37.8%) | 16 (51.6%) | 20 (52.6%) | 17 (37.0%) | 6 (33.3%) |
2015–2016 | 71 (19.2%) | 24 (20.3%) | 23 (19.3%) | 3 (9.7%) | 9 (23.7%) | 7 (15.2%) | 5 (27.8%) |
Metastatic organs at M1 dx, n (%) | |||||||
1 | 168 (45.4%) | 52 (44.1%) | 53 (44.5%) | 15 (48.4%) | 19 (50.0%) | 19 (41.3%) | 10 (55.6%) |
2 | 110 (29.7%) | 37 (31.4%) | 39 (32.8%) | 8 (25.8%) | 9 (23.7%) | 12 (26.1%) | 5 (27.8%) |
3+ | 92 (24.9%) | 29 (24.6%) | 27 (22.7%) | 8 (25.8%) | 10 (26.3%) | 15 (32.6%) | 3 (16.7%) |
Dominating site of disease at M1 dx, n (%)a | |||||||
Visceral | 244 (65.9%) | 69 (58.5%) | 72 (60.5%) | 28 (90.3%) | 30 (78.9%) | 35 (76.1%) | 10 (55.6%) |
Bone | 113 (30.5%) | 47 (39.8%) | 44 (37.0%) | 2 (6.5%) | 8 (21.1%) | 4 (8.7%) | 8 (44.4%) |
Soft tissue | 13 (3.5%) | 2 (1.7%) | 3 (2.5%) | 1 (3.2%) | 0 (0.0%) | 7 (15.2%) | 0 (0.0%) |
Performance status at M1 dx, n (%) | |||||||
0 | 105 (57.4%) | 33 (57.9%) | 33 (52.4%) | 12 (75.0%) | 14 (66.7%) | 11 (61.1%) | 2 (25.0%) |
1 | 56 (30.6%) | 19 (33.3%) | 21 (33.3%) | 3 (18.8%) | 5 (23.8%) | 3 (16.7%) | 5 (62.5%) |
2 | 18 (9.8%) | 4 (7.0%) | 7 (11.1%) | 0 (0.0%) | 2 (9.5%) | 4 (22.2%) | 1 (12.5%) |
3+ | 4 (2.2%) | 1 (1.8%) | 2 (3.2%) | 1 (6.2%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
Unknown | 187 (50.5%) | 61 (51.7%) | 56 (47.1%) | 15 (48.4%) | 17 (44.7%) | 28 (60.9%) | 10 (55.6%) |
Adjuvant treatment before M1 Dx, n (%) | |||||||
Endocrine therapy | 201 (54.3%) | 70 (59.3%) | 79 (66.4%) | 5 (16.1%) | 22 (57.9%) | 9 (19.6%) | 16 (88.9%) |
Radiotherapy | 221 (59.7%) | 67 (56.8%) | 72 (60.5%) | 14 (45.2%) | 19 (50.0%) | 34 (73.9%) | 15 (83.3%) |
Chemo therapy | 154 (41.6%) | 40 (33.9%) | 50 (42.0%) | 10 (32.3%) | 15 (39.5%) | 33 (71.7%) | 6 (33.3%) |
Antibody therapy | 26 (7.0%) | 1 (0.8%) | 4 (3.4%) | 7 (22.6%) | 11 (28.9%) | 3 (6.5%) | 0 (0.0%) |
Treatment lines received following metastatic diagnosis | |||||||
Number of treatment lines | |||||||
Mean (SD) | 4.2 (3.2) | 4.5 (3.4) | 4.6 (3.4) | 3.8 (2.6) | 4.9 (3.0) | 2.7 (2.5) | 2.0 (1.5) |
Median (IQR) | 3.0 (2.0–6.0) | 3.0 (2.0–7.0) | 3.0 (2.0–7.0) | 3.0 (2.0–5.0) | 4.5 (3.0–6.8) | 2.0 (1.0–4.0) | 1.0 (1.0–3.5) |
Range | 0–18 | 1–18 | 0–15 | 0–10 | 0–13 | 0–9 | 0–5 |
Proportion of time on active treatment following metastatic diagnosis by subtype | |||||||
Treatment, median (IQR) | |||||||
Any | 93 (75–98) | 96 (89–99) | 94 (83–99) | 74 (43–91) | 94 (83–98) | 53 (19–76) | |
Chemo | 20 (0.0–55) | 14 (0–48) | 20 (0–51) | 44 (16–79) | 21 (2–62) | 52 (19–73) | |
Antibody | 0 (0–0) | 0 (0–0) | 0 (0–0) | 39 (15–70) | 46 (16–76) | 0 (0–0) | |
Endocrine | 55 (10–92) | 72 (40–97) | 66 (32–97) | 0 (0–0) | 56 (26–87) | 0 (0–0) | |
Targeted | 0 (0–0) | 0 (0–0) | 0 (0–0) | 0 (0–8) | 0 (0–1) | 0 (0–0) | |
Survival (months) | |||||||
Death during follow-up, n (%) | 258 (69.7%) | 83 (70.0%) | 79 (66.4%) | 23 (74.1%) | 19 (50.0%) | 42 (91.3%) | 12 (66.7%) |
Median survival (95% CI) | 33 (28–36) | 43 (31–52) | 36 (30–51) | 31 (20–45) | 42 (30-NA) | 11 (8–18) | 21 (12.7-NA) |
2 yr OS (95% CI) | 61 (56–66) | 66 (58–76) | 67 (59–76) | 61 (46–81) | 78 (66–93) | 23 (13–39) | 47 (29–79) |
5 yr OS (95% CI) | 26 (21–32) | 28 (20–39) | 29 (21–40) | 21 (10–44) | 46 (31–67) | 7 (2–20) | 25 (10–62) |